Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
GLOBAL steel giant ArcelorMittal announced on Thurday(11) that Aditya Mittal, the son of company founder Lakshmi Mittal, will replace him as the group's chairman and CEO.
Currently, he is the chief financial officer (CFO) of the firm and will be replaced by Genuino Christino.
The elder Mittal, who founded the company in 1976, will become executive chairman of the Luxembourg-based company.
He will continue to lead the board of directors and work together with the CEO and management team, a statement said.
"It is an honour to be the CEO of the world's largest steel making company. Mr Mittal built ArcelorMittal from a greenfield rolling mill in Indonesia. It is an extraordinary achievement and I am privileged to have witnessed and been part of so much of that journey," said Aditya Mittal.
"The world is transforming at a rapid pace and it brings challenges but also many opportunities for ArcelorMittal. The biggest challenge, but also the biggest opportunity, will be to demonstrate that steel can de-carbonise and indeed is the perfect material for a circular economy."
Aditya Mittal joined his father's firm from Credit Suisse and was involved in the 2006 merger of Arcelor and Mittal Steel, which created the current company.
The announcement came as the company said it had reduced it's net loss in 2020 by a factor of three to $733 million, even though sales dropped by a quarter.
Despite the worldwide coronavirus slump, ArcelorMittal returned to profit in the fourth quarter of last year.
Looking forward to 2021, the company expects global steel demand to increase by between 4.5 and 5.5 per cent, after it dropped by one percent in 2020.
Lakshmi Mittal said he was proud of the group's performance and that he was pleased to be handing on the reins "in a position of relative strength."
"The board unanimously agree that Aditya Mittal is the natural and right choice to be the company's chief executive," the chairman said.
"We have worked closely together since he joined the company in 1997, indeed in recent years we have effectively been managing the company together."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.